Platform HCP assays can be utilized and offer advantages when compared to process specific assays for both early- and late-stage programs as detailed in USP (U.S. Pharmacopeia National Formulary, USP 39 Published General Chapter, <1132> Residual Host Cell Protein Measurement in Biopharmaceuticals, 2016). The WuXi Biologics Center of Excellence for HCP Detection originally developed a platform HCP assay for our WuXia CHO-K1 cell line. However, the breadth and depth of HCP antibodies coverage is so great that our platform assay is ideal for any CHO-K1 cell line used for biologics production. The performance our platform HCP assay is equal or greater than commercially available HCP detection kits. Our CHO-K1 platform HCP assay is ready-to-use and has gained FDA approvals for multiple commercially available biologics.